These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 35533508)

  • 1. Engineered therapeutic bacteria for the treatment of oral squamous cell carcinoma.
    Jayaseelan VP; A S SG; Arumugam P
    Oral Oncol; 2022 Jul; 130():105874. PubMed ID: 35533508
    [No Abstract]   [Full Text] [Related]  

  • 2. Early Discovery, Early Recovery: The principle behind successful oral squamous cell carcinoma treatment!
    Misra SR; Das R
    Oral Oncol; 2023 Oct; 145():106511. PubMed ID: 37478573
    [No Abstract]   [Full Text] [Related]  

  • 3. Comment on circulatory miRNAs as therapeutic molecules for oral potentially malignant disorder and oral squamous cell carcinoma.
    Yang X; Zhou T; Ji T; Jia H; Liu W
    Oral Oncol; 2022 Jul; 130():105901. PubMed ID: 35533509
    [No Abstract]   [Full Text] [Related]  

  • 4. Comment on letters to the editor in oral oncology referring to microRNAs as therapeutic molecules for oral squamous cell carcinoma.
    Zhang S; Han X; Wang M; Shen X
    Oral Oncol; 2023 Feb; 137():106298. PubMed ID: 36584496
    [No Abstract]   [Full Text] [Related]  

  • 5. Methuosis - A promising lead for the treatment of oral squamous cell carcinoma.
    Krishnan RP; Ramani P; Pandiar D
    J Stomatol Oral Maxillofac Surg; 2023 Feb; 124(1S):101333. PubMed ID: 36402427
    [No Abstract]   [Full Text] [Related]  

  • 6. A surge of hope: A case of lymph node hyperplasia after oral squamous cell carcinoma neoadjuvant immunotherapy.
    Cao LM; Zhong NN; Liu B; Sun YF; Bu LL
    Oral Oncol; 2023 Dec; 147():106613. PubMed ID: 37918287
    [No Abstract]   [Full Text] [Related]  

  • 7. Authors reply to the comment on letters to the editor in oral oncology referring to microRNAs as therapeutic molecules for oral squamous cell carcinoma.
    Sekar D
    Oral Oncol; 2023 Feb; 137():106306. PubMed ID: 36623474
    [No Abstract]   [Full Text] [Related]  

  • 8. Engineered Dex: A promising therapeutic strategy for oral squamous cell carcinoma.
    Vijayashree Priyadharsini J; Abilasha R; Anitha P; Paramasivam A
    J Stomatol Oral Maxillofac Surg; 2023 Feb; 124(1):101277. PubMed ID: 36058533
    [No Abstract]   [Full Text] [Related]  

  • 9. Oral squamous cell carcinoma in the young patient: an emerging unique cohort of patients.
    Kolokythas A
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2022 Jun; 133(6):617. PubMed ID: 35431174
    [No Abstract]   [Full Text] [Related]  

  • 10. Outcomes for recurrent oral cavity squamous cell carcinoma: A comprehensive outlook.
    Reghunadhan P; Hegde S; Thakur S; Subash A; Rao VUS
    Oral Oncol; 2023 Aug; 143():106440. PubMed ID: 37290381
    [No Abstract]   [Full Text] [Related]  

  • 11. Systematic review and individual patient data analysis of pediatric head and neck squamous cell carcinoma: An analysis of 217 cases.
    Bhanu Prasad V; Mallick S; Upadhyay AD; Rath GK
    Int J Pediatr Otorhinolaryngol; 2017 Jan; 92():75-81. PubMed ID: 28012539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic nature of microRNAs in Oral Squamous Cell Carcinoma (OSCC).
    Sekar D; Selvakumar SC; Auxzilia Preethi K
    Oral Oncol; 2022 Nov; 134():106106. PubMed ID: 36067592
    [No Abstract]   [Full Text] [Related]  

  • 13. Oncogenic virus in oral squamous cell carcinoma and the role of oncolytic HSV-1 viro-immunotherapy as an emerging treatment.
    Saravanan M; Kolade Omole R; Torimiro N
    Oral Oncol; 2022 Oct; 133():106021. PubMed ID: 35868096
    [No Abstract]   [Full Text] [Related]  

  • 14. Implications of STAT signalling pathways and its associated molecules in the treatment of Oral Squamous Cell Carcinoma (OSCC).
    Anees FF; Sekar D
    J Stomatol Oral Maxillofac Surg; 2023 Jun; 124(3):101392. PubMed ID: 36681122
    [No Abstract]   [Full Text] [Related]  

  • 15. Clinical trial outcomes in oral squamous cell carcinoma: A pragmatic ideation.
    Yuwanati M; Sarode SC; Sarode GS; Gadbail A; Gondivkar S
    Oral Oncol; 2022 Mar; 126():105752. PubMed ID: 35121397
    [No Abstract]   [Full Text] [Related]  

  • 16. Engineered exoASO-STAT6: a potent monotherapy for oral squamous cell carcinoma.
    Jayaseelan VP; Paramasivam A
    Future Oncol; 2022 Aug; 18(25):2767-2769. PubMed ID: 35766123
    [No Abstract]   [Full Text] [Related]  

  • 17. Paraoxonase-2 expression in oral squamous cell carcinoma.
    Campagna R; Pozzi V; Salvucci A; Togni L; Mascitti M; Sartini D; Salvolini E; Santarelli A; Lo Muzio L; Emanuelli M
    Hum Cell; 2023 May; 36(3):1211-1213. PubMed ID: 36774414
    [No Abstract]   [Full Text] [Related]  

  • 18. MICRORNA-31 AS A POTENTIAL THERAPEUTIC BIOMARKER FOR ORAL SQUAMOUS CELL CARCINOMA: CURRENT EVIDENCE AND FUTURE PROSPECTS.
    Krishnan M; Babu S; Jayaraman S; Daniel P; Solomon A; Chinnaiyan M
    Exp Oncol; 2022 Nov; 44(3):263-264. PubMed ID: 36325699
    [No Abstract]   [Full Text] [Related]  

  • 19. Contralateral neck failure in lateralized oral squamous cell carcinoma.
    Habib M; Murgasen J; Gao K; Ashford B; Shannon K; Ebrahimi A; Clark JR
    ANZ J Surg; 2016 Mar; 86(3):188-92. PubMed ID: 26138827
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mitophagy: A therapeutic target for oral squamous cell carcinoma.
    Balachander K; Paramasivam A
    Oral Oncol; 2022 Jun; 129():105881. PubMed ID: 35504127
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.